Navigation Links
Facet Solutions Announces 2 Year Data from US Pilot Study
Date:4/23/2010

HOPKINTON, Mass., April 23 /PRNewswire/ -- Facet Solutions, Inc. today announced that it has finished compiling two year data from its lumbar stenosis pilot study in the US. At two years, patients in the ACADIA™ study experienced significant and sustained improvement in Oswestry Disability Index, VAS back pain and VAS leg pain.  There were no re-operations in any of the patients, and all patients met the definition of success for ODI improvement.

"Treating lumbar stenosis today represents a compromise for lumbar stenosis patients," commented Dr. James Youssef of SpineColorado in Durango, CO. "With existing procedures, we can maintain motion in the segment, but must leave in at least 50% of the facets which often contributed to the problem in the first place.  Alternatively, we can remove all of the pathology but must fuse the patient to re-stabilize.  By contrast, using the ACADIA™ procedure, we are able to fully decompress, removing all pain generators, and implant ACADIA™ to re-establish stability and motion for the patient."  

"These results represent a leap forward for treating lumbar stenosis," stated Facet Solutions' President & CEO, Geoff Pardo. "The results at one year were impressive, but the fact that they were sustained across the board at two years is particularly noteworthy."  Facet Solutions, Inc. has developed ACADIA™ to provide patients with lumbar spinal stenosis and facet degeneration a motion preserving alternative to lumbar spinal fusion. The ACADIA™ procedure includes replacement of the degenerated posterior spinal joints with an anatomic implant that is designed to restore the natural motion, stability, and balance to the lumbar spine. Facet Solutions is actively enrolling its US Pivotal IDE trial at 16 centers across the United States.

Dr. James Youssef, SpineColorado in Durango, CO, will be presenting a worldwide clinical update at the upcoming Spine Arthroplasty Society meeting in New Orleans, LA on Friday, April 30th at 9:06am.

About Facet Solutions

Facet Solutions, Inc. is a privately held, venture-backed company focused on development and commercialization of surgical devices for the treatment of facet-related spinal disorders. Facet Solutions has received venture capital from its partners De Novo Ventures and Spray Venture Partners. Facet Solutions is certified to ISO 13485. ACADIA™ is an investigational device in the United States. It is limited by United States (U.S.) Federal Law for investigational use only.


'/>"/>
SOURCE Facet Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
2. Facet Solutions Completes Facet Joint and Disc Replacement Study
3. Facet Solutions Establishes Corporate Headquarters and Expands Executive Team
4. US Facet Fixation Market to Increase by Over 60% Annually Through 2012
5. Healthcare Data Solutions Announces Latest Database, PrescriberPRO@Home.
6. Haydon Kerk Motion Solutions, Inc. Introduces the New 20mm Stepper Motor Linear Actuator
7. Mettler Toledo and PDS Pathology Data Systems Integrate Powerful Solutions for Faster and More Accurate Preclinical Studies
8. Healthcare Data Solutions Announces New AnalyticPRO division.
9. Community Health Solutions of America Engages Chronically Ill Members With MEDais Risk Navigator Suite
10. MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities
11. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Basel, Switzerland (PRWEB) , ... ... ... leading provider of advanced software solutions for pharmaceutical research and development (R&D), ... project-based expertise in omic data analysis and interpretation for the rapidly evolving ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ ... a privately-held immunotherapeutics company targeting infectious diseases, announced ... the merger of PharmAthene and Altimmune in an ... Fund, HealthCap, Truffle Capital and Redmont Capital. The ... immunotherapeutics company with four clinical stage and one ...
(Date:1/19/2017)... , Jan. 19, 2017 AquaBounty Technologies, Inc. ... enhancing productivity in aquaculture and a majority-owned subsidiary of ... it has completed the listing of its common shares ... subscription from Intrexon. "AquaBounty,s listing on NASDAQ ... broaden our exposure to the U.S. markets as we ...
(Date:1/19/2017)... (PRWEB) , ... January 18, 2017 , ... ... for tech innovators, engineers, and scientists from around the world, was today awarded ... The awards program is based entirely on merit and decided upon by a ...
Breaking Biology Technology:
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
(Date:12/7/2016)... 2016   Avanade is helping Williams Martini ... in history, exploit biometric data in order to critically ... the competitive edge against their rivals after their impressive, ... Avanade has worked with Williams during the 2016 season ... (heart rate, breathing rate, temperature and peak acceleration) for ...
Breaking Biology News(10 mins):